Pause Rx review

Two things here are better than the category average. Both GLP-1 prices sit on cards a reader meets before any intake, and each product is footnoted with the molecule inside it rather than sold as a mechanism and left to be guessed at — the dual-agonist product says it contains tirzepatide, in as many words. The pricing promise is the one worth finding too: the same figure at every dose, which is what stops a low dose from quietly subsidizing somebody else's titration. Then read the tirzepatide card twice. Its heading introduces the price as a starting point and its body says that price covers all doses, and those cannot both be true of one number. If nothing moves with the dose there is nothing to start from; if something moves, the sentence underneath is wrong. The semaglutide card has no such problem, which makes this look like copy nobody reconciled rather than a policy — but it is the reader buying the more expensive drug who has to work out which half to believe. Fulfillment is described as a licensed 503(A) pharmacy, which is a class rather than a facility, and no dose is published behind either figure.

Vs median

$30/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

Pause Rx dispenses through a Not named (described as a licensed 503(A) compounding pharmacy) facility. No bloodwork is required before you start. A clinician review is included in the price.

Pause Rx sells compounded semaglutide and tirzepatide alongside a wide hormone, longevity and sexual-health catalog, and prices both GLP-1s on cards a reader meets before any intake. It also does something most of this category does not: it footnotes each product with the molecule it contains, so "Personalized GLP-1/GIP" is labeled as tirzepatide rather than left as a mechanism. The pricing claim is the best kind for anyone staying at a low dose — the same figure at every dose, which means a microdose is not quietly subsidizing someone else's titration. The trouble is that the tirzepatide card makes both claims at once. Its heading says "Starting at $249" and its body says "All doses just $249/month", and those are opposite statements about the same number. A reader cannot tell from the page whether $249 is the price or the floor. The semaglutide card has no such problem, which makes the contradiction look like an editing failure rather than a policy — but it is the tirzepatide buyer who has to guess.

The tirzepatide card is headed "Starting at $249" while its own body says "All doses just $249/month" — the page contradicts itself about its own price.

• No dose is published behind either figure.
• Fulfillment is described only as a 503(A) pharmacy; no facility is named.

Pause Rx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• What a flat price costs at a low dose
• The true annual cost of a plan